Brief: Windward Bio Launches With $200 Million Series A Financing
10/01/2025 14:09
Jan 10 (Reuters) - Windward Bio:
* WINDWARD BIO LAUNCHES WITH $200 MILLION SERIES A FINANCING
TO
DEVELOP PHASE 2-READY, LONG-ACTING ANTI-TSLP ANTIBODY WITH
BEST-IN-CLASS POTENTIAL IN ASTHMA AND COPD
* WINDWARD BIO: ORBIMED, NOVO HOLDINGS, AND BLUE OWL
HEALTHCARE
OPPORTUNITIES LEAD SERIES A FINANCING OF $200M
Source text: urn:newsml:reuters.com:*:nGNXbyhvDY
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sichuan Kelun-Biotech Biopharmaceutical
See all newsBrief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes To CZB Structured Deposit VI For RMB500 Mln
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Accepts New Indication Application For SAC-TMT
Brief: Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study
China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts HY Net Income Attributable Of RMB 388 MLN